Designing for Credibility in Biopharma
Biopharma companies have complicated stories to tell. The science is complex, the data is evolving, and different…
Service Provider Sprawl and the Case for Integrated Commercialization
No two commercialization plans look the same. Unlike other key functions that operate with disciplined processes and a…
The Identity Crisis at the Heart of Medical Affairs
Medical Affairs — the function that translates clinical evidence for physicians, payers, and regulators — has been…
Mind vs. Machine in Asset Strategy
A well-informed asset strategy is an essential component of developing a novel therapy to meet critical patient needs.
The Right Forum, at the Right Time
Some people need to “think out loud.” Others are eager to get right to the point. Toss in challenging schedules and…
100 Dots Connected: Reflecting on Eight Years of Conversations
The first edition of "Connecting the Dots" was published on September 29, 2017. Since Sue Nemetz penned that inaugural…
Assuming the Role of Patient
As readers of The NemetzGroup newsletter know, we often use this space to consider progress in biopharma, new…
The “Forcing Function” of JPM
Biopharma companies need to balance many critical priorities, especially those that are pre-commercial.
BIO and Boston: The Global Stage and HLYB
Attending a large conference, medical congress, or trade show can be both exhausting and exhilarating. The decision to…
Season of Transitions
Three notable transitions worthy of reflection at this point in time.